Oncolytics Biotech Overview
Oncolytics Biotech (ONCY) has a ROE of 560.92%, above the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow560.92%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for ONCY is 560.92%. That is above the Healthcare sector average of 11.15%. Investors often review this figure alongside Oncolytics Biotech's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ONCY currently prints 560.92% for ROE, while the sector average sits near 11.15%. That is roughly 4928.8% above the sector mean. Large gaps often invite a closer look at Oncolytics Biotech's growth, margins, and balance sheet.
Return on Equity shows how effectively Oncolytics Biotech converts resources into returns. At 560.92%, ONCY may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting ONCY's ROE (560.92%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Oncolytics Biotech's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
